We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.39% | 2.19 | 2.10 | 2.19 | 2.19 | 2.11 | 2.11 | 1,142,511 | 12:05:34 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.92 | 7.3M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/7/2018 07:00 | You get about ken.lol | volsung | |
03/7/2018 06:55 | Failed Phase 3.Just a Ponzi lifestyle business now.Avoid like the plague. | ken chung | |
02/7/2018 17:03 | I'm not sensitive nobby, I've been reading your posts without saying anything for a while now. But your last post was just pure gloating and needs to be checked. I'll say it again you're no financial advisor. Tip if you want but you're not always right. As an academic you can value the importance of choice of words. | immy1992 | |
02/7/2018 11:37 | You can't still be shorting this chung?? You're a brave soul if you are, risk firmly to the upside with all the disappointment already priced in.Best you'll get is circa 19p with market capitulation, otherwise being grumpy to eek out another few pennies smacks of desperation imo. | rathean | |
01/7/2018 22:26 | Falling fast now. Failed Phse 3 and no hope of commercialisation of anything else for years. | ken chung | |
01/7/2018 09:03 | Dear oh dear, you guys on here are so sensitive! And as for EVG, if you didn't notice they announced a positive trial result and the price did go up. OK it didn't hold the price presumably because they may need to raise more money but the research was essentially correct. Shareholders will only have to wait until the end of the year for the full result. Synairgen has a lot more to go IMHO with further clinical trial results for the fibrosis drug coming in the next quarter. Although (just for immy) it may go down before it goes up again 😜..... Nobby | nobbygnome | |
30/6/2018 19:51 | Careful nobby. You are no licensed financial advisor. Nor do you always get it right. Don't need to bring up EVG do i ? | immy1992 | |
29/6/2018 13:13 | I hope some of you took my advice about Synairgen. It is up about 50% this week.... | nobbygnome | |
29/6/2018 11:23 | All the action at UKOG folks. David Lenigas bought £500K worth yesterday (I'm sure he's privy to info). UKOG went from 1p-11p last year. UKOG last time went into double-digits and that was on a drill. This is flow rates for 'the one' | ssrover | |
29/6/2018 11:17 | My wager offer is still there folks if anyone wishes to take me up on it?! | 1retirement | |
29/6/2018 09:11 | Ken - "Lupuzor failed Phase 3." - Aye, that's now in the price ;-) - " He took Alizyme into administration a couple of years ago and another company only this year." - With approx £10mill in the pot, not any time soon ;-) GLA SR | stockriser | |
29/6/2018 08:51 | Feedback from the agm suggests a plan to commercialise lupizor by hook or by crook. They remain convinced of the science, let's hope plan b is far better thought through. I still retain a 50p target here. | rathean | |
29/6/2018 08:48 | Plenty of buy orders now pilling in on the bid | kirk 6 | |
29/6/2018 08:41 | Thanks harley | sicilian_kan | |
29/6/2018 08:34 | I agree - if this pushes through resistance at about 24.7p and stayes there, then watch the bots start buying - no bad news expected - good news on Monday? - primed and ready to fly. | stockriser | |
29/6/2018 08:33 | kirk you're a muppet | spawny100 | |
29/6/2018 08:29 | Big over the top prices being paid now Looks about to fly | kirk 6 | |
29/6/2018 00:05 | hxxps://www.lequotid | harleydocman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions